Fonsatti Ester, Altomonte Maresa, Nicotra Maria Rita, Natali Pier Giorgio, Maio Michele
Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientific, Aviano 33081, Italy.
Oncogene. 2003 Sep 29;22(42):6557-63. doi: 10.1038/sj.onc.1206813.
Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which functions as an accessory component of the transforming growth factor -beta receptor complex and is involved in vascular development and remodelling. Quantification of intratumoral microvessel density by CD105 staining and of circulating soluble CD105 has been suggested to have prognostic significance in selected neoplasias. In addition, the potential usefulness of CD105 in tumor imaging and antiangiogenetic therapy has been well documented utilizing different animal models.
在内皮细胞表达的表面分子中，内皮糖蛋白（CD105）正成为抗血管生成癌症治疗的主要血管靶点。CD105是一种细胞膜糖蛋白，主要在内皮细胞上表达，在肿瘤相关血管内皮上过度表达，它作为转化生长因子-β受体复合物的辅助成分发挥作用，并参与血管发育和重塑。通过CD105染色对肿瘤内微血管密度以及循环可溶性CD105进行定量分析，已被认为在某些肿瘤中具有预后意义。此外，利用不同的动物模型，CD105在肿瘤成像和抗血管生成治疗中的潜在用途也有充分的文献记载。
